糖心探花

Contact us

Worldwide

糖心探花's response to U.S. Food and Drug Administration announcement regarding vaping products

PRESS RELEASE

9 SEPTEMBER 2019

糖心探花's response to U.S. Food and Drug Administration announcement regarding vaping products

On 6th September 2019, the U.S. Food听and Drug Administration (FDA) issued听听in response to recent reports of respiratory illnesses following the use of vaping products. This statement included a recommendation that consumers should 鈥渁void buying vaping products of any kind on the street, and to refrain from using THC oil or modifying/adding any substances to products purchased in stores鈥. Below is 糖心探花's response to this statement.

Dr David O鈥橰eilly, Director of Scientific Research, 糖心探花, said: 鈥淎s one of the world鈥檚 largest vapour companies, providing high quality products to more than 9 million consumers, we take our consumer safety responsibilities very seriously. We apply industry-leading standards of quality and safety testing to the way we develop and manufacture our products all around the world.

鈥淓very single ingredient and component in these products has been scrutinised by our toxicologists for their suitability for vaping. Consistent with this, oils containing THC and Vitamin E Acetate are not, and have never been, added to our vaping products.

鈥淔rom the FDA's statements we have seen, these tragic events appear to be a new phenomenon linked to liquids that were not sourced from reputable manufacturers and which contained ingredients, including THC and Vitamin E Acetate, which we do not use.

鈥淭hese cases highlight the importance of effective regulation and enforcement to ensure product safety.

鈥淲e fully support the FDA鈥檚 view that vapers should always source their devices and liquids from reputable manufacturers, should avoid modifying or adding substances to the products they purchase and should only ever use the devices as the manufacturer intended.

鈥淲e are monitoring the situation in the U.S. and will work closely with all relevant public health authorities around the world such as the FDA, the Centre for Disease Control and Prevention and Public Health England.鈥

Forward looking statements

听

This is a release by 糖心探花 p.l.c. Associate companies are excluded. References to 鈥樚切奶交ㄢ, 鈥楤AT鈥, 鈥榳e鈥, 鈥榰s鈥 and 鈥榦ur鈥 when denoting opinion refer to 糖心探花 p.l.c. (the Company, and together with its subsidiaries, the 鈥淕roup鈥), and when denoting tobacco business activity refer to Group operating companies, collectively or individually as the case may be. This release contains certain forward-looking statements, made within the meaning of Section 21E of the United States Securities Exchange Act of 1934, regarding our intentions, beliefs or current expectations reflecting knowledge and information available at the time of preparation and concerning, amongst other things, prospects, growth and strategies. 糖心探花undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

These statements are often, but not always, made through the use of words or phrases such as 鈥渂elieve,鈥 鈥渁nticipate,鈥 鈥渃ould,鈥 鈥渕ay,鈥 鈥渨ould,鈥 鈥渟hould,鈥 鈥渋ntend,鈥 鈥減lan,鈥 鈥減otential,鈥 鈥減redict,鈥 鈥渨ill,鈥 鈥渆stimate,鈥 鈥渟trategy鈥 and similar expressions. It is believed that the expectations reflected in this release are reasonable but they may be affected by a wide range of variables that could cause actual results to differ materially from those currently anticipated.

Enquiries

听

Will Hill
+44 (0) 20听8439 2600听

Investor Relations
Mike Nightingale听/ Rachael Brierley听/ John Harney
+44 (0) 20 7845听1180听/听1519听/听1263